PT-141 (Bremelanotide): Selective Melanocortin-Receptor Research

PT-141 (Bremelanotide) is a cyclic heptapeptide analogue of α-MSH with greater selectivity for MC3R and MC4R than the parent hormone. Its research footprint spans CNS pharmacology, sexual-function signalling and cardiovascular pharmacodynamics — all connected through central melanocortin circuits.

In laboratory research, PT-141 is a useful complement to Melanotan II. Where Melanotan II engages all melanocortin receptors and is often used for MC1R-pigmentation work, PT-141's shift toward MC4R makes it more suitable for isolating central melanocortin effects on appetite, arousal and blood-pressure regulation.

Published preclinical work has examined PT-141 in rodent models of sexual behaviour, in blood-pressure pharmacodynamics and in appetite-related endpoints. The peptide's melanocortin selectivity makes it a helpful tool for structure-activity work when paired with MC-receptor-selective antagonists.

From a research-practice perspective, PT-141 is supplied lyophilised. Reconstitution in bacteriostatic water is standard; aliquoting and cold storage extend usable life. Reference-grade vials should ship with HPLC purity, mass-spectrometry identity and a batch COA.

PT-141 remains a chemical reference standard for laboratory research. This article is educational reference material only and is not a therapeutic recommendation.